Glucagon like Peptide 1 agonists and cardiovascular disease

Abstract

Glucagon-like peptide 1 (GLP-1) is among the most studied incretins. Endogenous GLP-1 and its pharmacological agonists are characterized by presenting various direct and indirect effects, widely studied, which could explain this reduction in cardiovascular risk of patients with type 2 diabetes mellitus (T2DM). GLP-1 receptor agonists (RA) liraglutide, semaglutide, albiglutide and  dulaglutide demonstrated benefits on cardiovascular prognosis in the results of the LEADER, SUSTAIN-6, HARMONY, REWIND and PIONEER studies 6. This evidence has positioned them in international guidelines as antidiabetic drugs of choice in patients with T2DM and established cardiovascular disease or high cardiovascular risk.